Skip to content
AnalystLens

CME GROUP INC. 8-K Report, Regulation FD Disclosure (Dec 11, 2024)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed December 11, 2024
Period End
December 11, 2024
Security
CME
In the record · 2016–202610-K1110-Q328-K119

CME filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’17Nov ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Apr ’22Apr ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed December 11, 2024. Cited figures are marked; the original filing is the authoritative source.

CME Group Inc. (CME) has filed an 8-K report on December 11, 2024, to disclose recent communications regarding changes to its Clearing House collateral fee schedule and client pricing.

These changes were communicated to Clearing Members via Advisory Notice 24-383 and to clients through Special Executive Report 9482 on December 10, 2024. While the specifics of the fee and pricing adjustments are not detailed within the 8-K itself, investors should note that these communications represent material updates to the company's operational and revenue-generating framework. The company has made these notices available on its website, signaling transparency regarding these important financial adjustments.

Key Highlights

  1. CME Group announced changes to its Clearing House collateral fee schedule.
  2. Pricing changes were communicated to clients.
  3. The effective date of these communications was December 10, 2024.
  4. Clearing Members were notified via Advisory Notice 24-383.
  5. Clients were informed through Special Executive Report 9482.
  6. The full notices are available on CME Group's website.
  7. This filing primarily serves as a Regulation FD disclosure.

Frequently Asked Questions

  1. What is the primary purpose of this 8-K filing?

    The primary purpose of this 8-K filing is to comply with Regulation FD disclosure requirements. It informs the public that CME Group has communicated changes to its Clearing House collateral fee schedule and client pricing to its members and clients.

  2. What specific changes were made to the collateral fee schedule or client pricing?

    The 8-K filing does not provide the specific details of the collateral fee or pricing changes. It only states that these changes were communicated to Clearing Members and clients. Investors will need to refer to the Advisory Notice 24-383 and Special Executive Report 9482, available on CME Group's website, for details.

  3. When were these changes communicated?

    The changes to the Clearing House collateral fee schedule and client pricing were communicated on December 10, 2024.

  4. How can investors find more information about these changes?

    Investors can find more information by accessing Advisory Notice 24-383 and Special Executive Report 9482, which have been posted to the CME Group Inc. website.